NewsRoom Articles - Page 122 of 224

FridayMay 27, 2022 11:58 am

Study Suggests COVID-19 Increases Parkinson’s Disease Risk

New research has found that the virus known to cause COVID-19 may heighten the risk of brain degeneration observed in patients with Parkinson’s disease. For their study, the researchers used genetically engineered mice that could express the human ACE-2 receptor. It is this receptor that the SARS-CoV-2 virus uses to access the cells found in human airways. The researchers infected the mice with a SARS-CoV-2 dose that corresponded to a moderate coronavirus infection in people and then allowed them to recover. Of the total number of mice that were infected with the virus, 80% survived. After the mice had been…

ThursdayMay 26, 2022 1:02 pm

UNICEF Sounds the Alarm on the Worldwide Child Malnutrition Risk

UNICEF recently warned that the worldwide risk for child malnutrition, which was already increasing before Russia invaded Ukraine, had significantly risen. In its recent press release, UNICEF noted that 10% of children in Cambodia were actively impacted by malnutrition. The organization stated that severe wasting, which could be observed when a child was too thin for their height, is the most life threatening and visible form of malnutrition. In its Child Alert press release, the United Nations Children’s Fund estimated that globally, at least 13.5 million children aged five and below suffered from severe wasting. The press release added that…

ThursdayMay 26, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Efforts Boosted by New Study Indicating Effectiveness of Psychedelic Compounds

Recent study indicates psychedelic compounds show significant promise in treating a range of mental-health disorders Participants given psilocybin therapy reported a rapid, sustained improvement in their depression Cybin’s CYB003 has demonstrated less variability, faster onset, shorter duration and better brain penetration than oral psilocybin A new study sponsored by Imperial College London reports that psychedelic compounds may be effective in treating mental-health disorders (https://ibn.fm/xSdZv). The study supports efforts made by Cybin (NEO: CYBN) (NYSE American: CYBN), which is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental-health disorders.…

WednesdayMay 25, 2022 2:40 pm

New Research Outlines Autoimmune Hepatitis Risk Factors after Liver Transplantation

Data from the National Organization for Rare Disorders shows that roughly one to two individuals out of every 100,000 globally are diagnosed with autoimmune hepatitis annually. This rare liver disorder is characterized by an autoimmune response against healthy cells in the liver, which leads to cirrhosis, liver failure and eventually, death. Some patients with this disorder undergo liver transplants to treat the illness when it’s in its advanced stages. However, in some cases, the disease recurs, and not much has been known about what factors heightened the possibility of the disease recurring — until now. New research has outlined some risk…

TuesdayMay 24, 2022 11:53 am

Genomic Sequencing Offers Hope in Diagnosis, Treatment of Brain Tumors

New research has found that genomic profiling may play a key role in the diagnosis and grading of brain tumors. More accurate and new diagnoses can be generated from genomic profiling. Here, alterations in the DNA that drive the growth of tumors are identified. Previously, diagnosis was determined using microscopic comparisons between normal cells and cancer cells. This research was carried out by scientists at the University of California-San Francisco, who followed 38 patients with glioblastoma, IDL-wild type tumors. This type of tumor was recategorized from a grade 2/3 glioma to a central nervous system grade 4 tumor. The researchers…

MondayMay 23, 2022 11:40 am

New Research Suggests Mental Disorders Magnify Dementia Risk

A new study has found that various psychiatric disorders may be associated with an increased risk of developing dementia. The study, which was led by Leah Richmond-Rakerd, reported its findings in “JAMA Psychiatry.” For their study, the researchers conducted an analysis of data to determine the link between a range of psychiatric disorders and the development of dementia. The analysis’ results indicate that psychiatric disorders are linked to a heightened risk of developing Alzheimer’s disease and other dementias. The researchers utilized data obtained from the Integrated Data Infrastructure of New Zealand for their research. This database is comprised of health…

MondayMay 23, 2022 9:45 am

Aditxt Inc. (NASDAQ: ADTX) Planning Nationwide Rollout of its AditxtScore(TM) Immune Monitoring Platform

Aditxt recently entered a multi-year partnership with GRS for the promotion of its proprietary AditxtScore Immune Monitoring Platform Aditxt plans to roll out the monitoring platform to medical offices, pharmacies, laboratories, and employers across the country, with promotion through nationwide television commercials AditxtScore(TM) monitors the current immune response not genetic sequencing Continuing research into COVID-19 is being done worldwide, with some researchers showing concern among the population of vaccinated individuals testing positive for the virus – including concerns about the durability of protection against highly contagious emerging strands. Researchers are still learning more about vaccinations against viruses and diseases in…

FridayMay 20, 2022 11:36 am

Study Finds That Some Mental Disorders Share Genetic Profiles

A new study has found that most individuals who are diagnosed with one mental health condition may find that they also have other psychiatric conditions. The study discovered that a number of mental health conditions share some genetic similarities, and this finding explains why multiple conditions are common among individuals suffering from psychiatric disorders. Over one-half of individuals with a mental illness often have two or three conditions, with almost one-third suffering from four or more conditions. This makes it harder for clinicians to identify and treat these indications. However, this new discovery may help researchers develop new therapies for…

ThursdayMay 19, 2022 11:14 am

Lantern Pharma to Host Glioblastoma Multiforme Webinar to Mark Brain Tumor Awareness Month

Last week, Lantern Pharma Inc. announced that it would host a virtual webinar on May 26, 2022, at 12 p.m. ET. Lantern Pharma Inc. is an oncology-focused clinical stage biopharmaceutical firm that is leveraging its proprietary AI and machine learning platform to transform the discovery and development of oncology drugs. The company’s approach is to deliver the best-in-class outcomes. It is currently developing an ADC program and four drug candidates across nine disclosed tumor targets. The key opinion leader webinar, which will be held toward the end of Brain Tumor Awareness Month, will mainly focus on glioblastoma multiforme and the…

WednesdayMay 18, 2022 1:23 pm

FDA Expands Access to MDMA for Treatment of PTSD

A number of clinics in various cities in America have received approval from the FDA to expand patients’ access to MDMA. MDMA is a psychedelic drug commonly referred to as ecstasy. Researchers have found that this drug may be useful in the treatment of a number of mental health conditions, including post-traumatic stress disorder, or PTSD. While this program is currently in phase III trials, the effectiveness and safety demonstrated thus far will enable the drug to be used for compassionate use. Compassionate use is an approval term used by the FDA for treatments that may help patients who haven’t…